论文部分内容阅读
目的:探讨阿奇霉素联合孟鲁司特钠治疗儿童肺炎支原体肺炎(MMP)的疗效。方法:选取2013年3月至2014年3月收治的100例MMP患儿,将其随机分为对照组和实验组各50例,对照组采用静脉滴注阿奇霉素治疗,实验组在对照组基础上口服孟鲁司特钠片。比较两组患儿的治疗效果、哮喘发生率及不良反应。结果:实验组患儿治疗后退热时间、止咳时间、住院时间分别为(1.69±0.99)d、(3.39±1.48)d、(6.15±2.02)d,明显低于对照组的(3.95±2.45)d、(5.92±3.32)d、(8.86±1.78)d,差异均有统计学意义(均P<0.05);实验组患儿儿童支原体肺炎诱发哮喘的发病率为10%(5/50),显著低于对照组的48%(24/50),差异有统计学意义(P<0.05);两组在治疗过程中均未见明显不良反应。结论:阿奇霉素联合孟鲁司特钠治疗儿童MMP能明显提高患者的治疗效果,且能有效降低儿童支原体肺炎诱发哮喘的发病率,值得临床推广。
Objective: To investigate the efficacy of azithromycin combined with montelukast sodium in children with mycoplasma pneumoniae pneumonia (MMP). Methods: A total of 100 cases of MMPs from March 2013 to March 2014 were selected and randomly divided into control group and experimental group (n = 50). The control group was treated with intravenous azithromycin. The experimental group was based on the control group Oral montelukast sodium tablets. The treatment effect, asthma incidence and adverse reactions in both groups were compared. Results: The antipyretic time, cough time and hospital stay in experimental group were (1.69 ± 0.99) d, (3.39 ± 1.48) d and (6.15 ± 2.02) d respectively, which were significantly lower than those in control group (3.95 ± 2.45) (5.92 ± 3.32) d, (8.86 ± 1.78) d, the difference was statistically significant (all P <0.05). The incidence of children with mycoplasma pneumonia in the experimental group was 10% (5/50) Significantly lower than that of the control group (48%, 24/50), the difference was statistically significant (P <0.05). No adverse reactions were observed in the two groups during the treatment. Conclusion: Azithromycin combined with montelukast sodium in children with MMP treatment can significantly improve the therapeutic effect of patients, and can effectively reduce the incidence of children with mycoplasma pneumonia-induced asthma, worthy of clinical promotion.